Irhythm Technologies, INC 8-K filings

iRhythm Holdings announces a definitive agreement to acquire Vital Connect, Inc. for a combination of cash and stock, expanding its remote cardiac monitoring capabilities.

iRhythm Holdings, Inc. reported a material cybersecurity incident involving unauthorized access to third-party hosted applications, with a threat actor claiming to possess sensitive data.

iRhythm Technologies has reached a $45 million settlement to resolve a pending class action securities lawsuit.

iRhythm Holdings stockholders approved the 2026 Equity Incentive Plan and ratified the appointment of KPMG LLP at the 2026 Annual Meeting.

iRhythm Holdings, Inc. announced the appointment of Jason Patten, Executive Vice President at UnitedHealth Group, to its Board of Directors and Audit Committee, effective March 12, 2026.

iRhythm Holdings, Inc. reported strong fourth quarter and full year 2025 financial results, achieving record revenue and its first-ever quarter of positive GAAP net income.

iRhythm Technologies, Inc. announced a corporate reorganization into a holding company structure, provided strong preliminary Q4 2025 results, and issued an optimistic 2026 financial outlook.

iRhythm Technologies, Inc. details its strategic initiatives for market expansion, innovation, and financial improvement, targeting significant revenue growth and profitability by 2025.

iRhythm Technologies reported robust third-quarter 2025 financial results with revenue up 30.7% year-over-year and increased its full-year 2025 guidance, alongside an updated executive severance policy.

iRhythm Technologies, Inc. announced strong second quarter 2025 financial results, including record revenue and improved profitability, leading to an increase in its full-year 2025 financial guidance.

iRhythm Technologies, Inc. announced the retirement of two long-serving board members, Mark Rubash and Ralph Snyderman, and the concurrent appointment of Karen McGinnis and Kevin OBoyle, effective July 7, 2025, to enhance its strategic and financial oversight.

iRhythm Technologies, Inc. announced the successful election of all director nominees, ratification of PricewaterhouseCoopers LLP as its independent auditor, and advisory approval of named executive officer compensation at its 2025 Annual Meeting of Stockholders.

iRhythm Technologies announced a 20.3% increase in revenue for Q1 2025, driven by strong demand for Zio services and expansion in value-based care.

iRhythm Technologies announces a 24% increase in Q4 revenue and provides optimistic 2025 revenue guidance.

Mojdeh Poul will not seek re-election to iRhythm Technologies' Board of Directors due to her appointment as President and CEO of Integra LifeSciences Holdings Corporation.

iRhythm Technologies anticipates full year 2024 revenue slightly above the high end of previous guidance and projects strong revenue growth for 2025.

iRhythm Technologies, Inc. has amended its 2016 Equity Incentive Plan to remove the 'Evergreen Provision' and updated its Code of Conduct to reflect current business values and operational priorities.

iRhythm Technologies announced a robust third quarter in 2024, marked by an 18% revenue increase and significant progress in global market expansion.

iRhythm Technologies released a shareholder presentation detailing its business overview, market expansion opportunities, and ongoing corporate transformation efforts.

iRhythm Technologies has entered into an exclusive license agreement with BioIntelliSense to integrate advanced sensor technology into its ambulatory cardiac monitoring platform.

iRhythm Technologies announced a 19.3% revenue increase in Q2 2024, along with a CFO transition and raised full-year guidance.

iRhythm Technologies held its 2024 Annual Meeting, electing directors, ratifying the appointment of its accounting firm, and approving an amendment to its charter, while also receiving a negative advisory vote on executive compensation.

iRhythm Technologies announced a strong first quarter with an 18.4% revenue increase year-over-year, driven by demand for its Zio services, and raised its full-year revenue guidance.

iRhythm Technologies successfully closed a $661.25 million offering of convertible senior notes due 2029, including the full exercise of the initial purchasers' option.

iRhythm Technologies has priced a $575 million convertible senior notes offering, upsized from $450 million, to qualified institutional buyers.

iRhythm Technologies plans to raise $450 million through a private offering of convertible senior notes, with an option for an additional $67.5 million, to repay debt and for general corporate purposes.

iRhythm Technologies announced its fourth quarter and full year 2023 financial results, highlighting a 20% revenue increase for the year and progress in new account onboarding.